Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Isoniazid and rifampicin exposure during treatment in drug-susceptible TB.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2023
Same author

Population Pharmacokinetic Model and Optimal Sampling Strategies for Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis.

Antimicrobial agents and chemotherapy·2022
Same author

Clinical standards for drug-susceptible TB: putting patients first.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2022
Same author

Assessment of TB treatment on patient well-being.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2021
Same author

Reply to Van Daele et al., "Fluconazole Underexposure in Critically Ill Patients: a Matter of Using the Right Targets?"

Antimicrobial agents and chemotherapy·2021
Same author

Optimization of Fluconazole Dosing for the Prevention and Treatment of Invasive Candidiasis Based on the Pharmacokinetics of Fluconazole in Critically Ill Patients.

Antimicrobial agents and chemotherapy·2020

Related Experiment Video

Updated: Jul 5, 2026

An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient
07:16

An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient

Published on: November 30, 2022

[Preventing pneumonia in ventilated patients].

T S van der Werf1, C J Stek

  • 1Universitair Medisch Centrum Groningen, Postbus 30.001, 9700 RB Groningen. t.s.van.der.werf@int.umcg.nl

Nederlands Tijdschrift Voor Geneeskunde
|May 9, 2008
PubMed
Summary

Oropharyngeal chlorhexidine reduces ventilator-associated pneumonia (VAP) incidence in ventilated patients but does not improve survival. Further research is needed to identify patient subgroups and optimal chlorhexidine formulations for VAP prevention.

Related Experiment Videos

Last Updated: Jul 5, 2026

An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient
07:16

An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient

Published on: November 30, 2022

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Critical Care Medicine

Background:

  • Oropharyngeal chlorhexidine demonstrates primary activity against Gram-positive bacteria, with limited efficacy against Gram-negative microorganisms.
  • Seven randomized clinical trials indicate a significant reduction in ventilator-associated pneumonia (VAP) incidence following oropharyngeal chlorhexidine application.
  • Current evidence does not support a survival benefit associated with oropharyngeal chlorhexidine use in ventilated patients.

Discussion:

  • Unanswered questions persist regarding the selection of patient subgroups who may benefit most from oropharyngeal chlorhexidine.
  • Optimal chlorhexidine formulations and dosages for VAP prevention remain to be established.
  • International recommendations for topical oropharyngeal chlorhexidine in ventilated patients are supported by recent Dutch studies.

Key Insights:

  • Chlorhexidine is effective in reducing VAP incidence but not mortality.
  • Patient selection criteria and optimal dosing strategies for chlorhexidine require further investigation.
  • Recent Dutch studies corroborate international guidelines on oropharyngeal chlorhexidine use.

Outlook:

  • Future research should focus on identifying specific patient populations that benefit from oropharyngeal chlorhexidine.
  • Investigating various chlorhexidine formulations and dosages is crucial for optimizing VAP prevention strategies.
  • Continued evaluation of chlorhexidine's role in critical care settings is warranted.